l-706000 and Long-QT-Syndrome

l-706000 has been researched along with Long-QT-Syndrome* in 2 studies

Other Studies

2 other study(ies) available for l-706000 and Long-QT-Syndrome

ArticleYear
Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel.
    Biochemical pharmacology, 2009, May-15, Volume: 77, Issue:10

    Drug-induced long QT syndrome has been principally ascribed to block of the cardiac hERG K(+) channel. Methanesulfonanilides, such as MK-499, E-4031 and dofetilide, are potent hERG antagonists that likely bind along the S6 helix within the inner vestibule of the pore. To further investigate these interactions, we broadly explored the structure-activity relationships of closely related analogs of MK-499 using a high-throughput ion flux assay, and evaluated in greater detail using patch-clamp electrophysiology. We observed that substitutions at the 4-position on the benzopyran ring significantly affected the potency of these analogs with the rank order of unsubstituted approximately ketone>amine>hydroxyl, implicating an important interaction at this position. We also evaluated the potency of these analogs on an S6 mutant of hERG (F656A) previously shown to significantly reduce the affinity for MK-499 and other known hERG antagonists (e.g. cisapride, terfenadine). In contrast to MK-499 (4-hydroxyl) and either the amine or unsubstituted analogs, the potency of the ketone analog was unaffected by this mutation suggesting that a compensatory interaction may be unveiled with the aromatic to apolar substitution, possibly through hydrogen bonding with Ser624 based on molecular modeling. More significantly, we found that this mutation rendered hERG susceptible to block in the closed-state by the smaller, unsubstituted analog, but not by MK-499 or larger analogs. Together these data suggest that interaction with Phe656 is not an absolute requirement for the binding of all methanesulfonanilide compounds, and that this residue may play a broader role in regulating access to the inner vestibule.

    Topics: Animals; Benzopyrans; Cell Culture Techniques; Chlorides; CHO Cells; Cricetinae; Cricetulus; Ether-A-Go-Go Potassium Channels; Humans; Ion Channel Gating; Long QT Syndrome; Models, Molecular; Mutation; Patch-Clamp Techniques; Piperidines; Potassium Channel Blockers; Protein Binding; Protein Structure, Tertiary; Rubidium; Structure-Activity Relationship; Transfection

2009
Expression and coassociation of ERG1, KCNQ1, and KCNE1 potassium channel proteins in horse heart.
    American journal of physiology. Heart and circulatory physiology, 2002, Volume: 283, Issue:1

    In dogs and in humans, potassium channels formed by ether-a-go-go-related gene 1 protein ERG1 (KCNH2) and KCNQ1 alpha-subunits, in association with KCNE beta-subunits, play a role in normal repolarization and may contribute to abnormal repolarization associated with long QT syndrome (LQTS). The molecular basis of repolarization in horse heart is unknown, although horses exhibit common cardiac arrhythmias and may receive drugs that induce LQTS. In horse heart, we have used immunoblotting and immunostaining to demonstrate the expression of ERG1, KCNQ1, KCNE1, and KCNE3 proteins and RT-PCR to detect KCNE2 message. Peptide N-glycosidase F-sensitive forms of horse ERG1 (145 kDa) and KCNQ1 (75 kDa) were detected. Both ERG1 and KCNQ1 coimmunoprecipitated with KCNE1. Cardiac action potential duration was prolonged by antagonists of either ERG1 (MK-499, cisapride) or KCNQ1/KCNE1 (chromanol 293B). Patch-clamp analysis confirmed the presence of a slow delayed rectifier current. These data suggest that repolarizing currents in horses are similar to those of other species, and that horses are therefore at risk for acquired LQTS. The data also provide unique evidence for coassociation between ERG1 and KCNE1 in cardiac tissue.

    Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Benzopyrans; Cell Line; Cisapride; Cricetinae; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Horses; Humans; Immunoblotting; Immunohistochemistry; In Vitro Techniques; KCNQ Potassium Channels; KCNQ1 Potassium Channel; Long QT Syndrome; Myocardium; Patch-Clamp Techniques; Piperidines; Potassium; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Protein Binding; RNA, Messenger; Swine

2002